(S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN paper)))) (VP (VBZ is) (S (VP (TO to) (VP (VB develop) (NP (NP (DT a) (NN methodology)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADJP (JJ useful) (PP (IN for) (S (VP (VBG analysing) (PP (IN from) (NP (DT a) (JJ microeconomic) (NN perspective))) (NP (NP (DT the) (NNS incentives)) (PP (TO to) (NP (VB entry) (, ,) (NN permanence) (CC and) (NN exit))) (PP (IN in) (NP (NP (DT the) (NN market)) (PP (IN for) (NP (JJ pharmaceutical) (NNS generics))))) (PP (IN under) (NP (JJ fuzzy) (NNS conditions)))))))))))))))) (. .))
(S (PP (IN In) (NP (NP (DT an) (JJ empirical) (NN application)) (PP (IN of) (NP (PRP$ our) (VBN proposed) (NN methodology))))) (, ,) (NP (NP (DT the) (JJ potential)) (PP (NNS towards) (NP (NN permanence))) (PP (IN of) (NP (NP (NN labs)) (PP (IN with) (NP (JJ different) (NNS characteristics)))))) (VP (VBZ has) (VP (VBN been) (VP (VBN estimated)))) (. .))
(S (NP (NP (DT The) (NN case)) (SBAR (S (NP (PRP we)) (VP (VBP deal) (PP (IN with)))))) (VP (VBZ is) (VP (VBN set) (PP (IN in) (NP (NP (DT an) (JJ open) (NN market)) (SBAR (WHADVP (WRB where)) (S (NP (JJ global) (NNS players)) (VP (VBP diversify) (PP (IN into) (NP (NP (JJ different) (JJ national) (NNS markets)) (PP (IN of) (NP (JJ pharmaceutical) (NNS generics)))))))))))) (. .))
(S (NP (NN Risk) (NNS issues)) (VP (VBP are) (ADJP (RB significantly) (JJ important) (PP (IN in) (S (VP (VBG deterring) (NP (NN decision) (NNS makers)) (PP (IN from) (S (VP (VBG expanding) (PP (IN in) (NP (DT the) (JJ generic) (JJ pharmaceutical) (NN business))))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP (RB not) (DT all) (NNS players)) (VP (VBP are) (VP (VBN affected) (PP (IN in) (NP (DT the) (JJ same) (NN way)) (NN and/or) (PP (TO to) (NP (DT the) (JJ same) (NN extent)))))) (. .))
(S (NP (JJ Small) (, ,) (JJ non-diversified) (NNS generics) (NNS labs)) (VP (VBP are) (PP (IN in) (NP (DT the) (JJR worse) (NN position)))) (. .))
(S (NP (PRP We)) (VP (VBP have) (VP (VBN highlighted) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (VBN expected) (NNP NPV)) (CC and) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS generics))) (PP (IN in) (NP (NP (DT the) (NN portfolio)) (PP (IN of) (NP (DT a) (JJ pharmaceutical) (NN lab))))))) (VP (VBP are) (NP (JJ important) (NNS variables))))) (, ,) (CC but) (SBAR (IN that) (S (NP (NP (PRP it))) (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ important)) (S (VP (TO to) (VP (VB consider) (NP (NP (DT the) (NN degree)) (PP (IN of) (NP (NN diversification))))))))))))) (. .))
(S (NP (NP (NNS Labs)) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN potential)) (PP (IN for) (NP (NP (NN diversification)) (PP (IN across) (NP (NNS markets)))))))) (VP (VBP have) (NP (NP (DT an) (NN advantage)) (PP (IN over) (NP (JJR smaller) (NN labs))))) (. .))
(S (NP (PRP We)) (VP (VBP have) (VP (VBN described) (NP (NP (DT a) (JJ fuzzy) (NN decision) (NN support) (NN system)) (VP (VBN based) (PP (IN on) (NP (DT the) (NNP Mamdani) (NN model))))) (SBAR (IN in) (NN order) (S (VP (TO to) (VP (VB determine) (NP (DT the) (NNS incentives) (SBAR (IN for) (S (NP (DT a) (NN laboratory)) (VP (TO to) (VP (VP (VB remain) (PP (IN in) (NP (DT the) (NN market)))) (SBAR (DT both) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (ADJP (JJ stable))))) (CC and) (SBAR (WHADVP (WRB when)) (S (NP (PRP it)) (VP (VBZ is) (VP (VBG growing))))))))))))))))) (. .))
